

1 TO THE HOUSE OF REPRESENTATIVES:

2 The Committee on Human Services to which was referred Senate Bill No.
3 295 entitled “An act relating to pretrial services, risk assessments, and criminal
4 justice programs” respectfully reports that it has considered the same and
5 recommends that the House propose to the Senate that the report of the
6 Committee on Judiciary be amended as follows:

7 First: In Sec. 1, legislative findings, by creating a new subsection to be
8 subsection (f) to read:

9 (f) Approximately 54,000 Vermonters have abused, or been dependent on,
10 alcohol or illicit drugs in the past year, according to the current National
11 Survey on Drug Use and Health. More people abuse or are dependent on
12 alcohol (approximately 39,000) than all illicit drugs combined (18,000). Many
13 Vermonters struggle with both alcohol and illicit drugs. Substance abuse is
14 expensive, and not solely due to the cost of providing treatment. It is estimated
15 that the State spending related to substance abuse accounts for approximately
16 18.4 percent of the Vermont budget, the majority of which is spent on the
17 indirect cost of substance abuse in the categories of criminal justice, education,
18 health, family, mental health, and State workforce. Research indicates that
19 \$1.00 invested in addiction treatment saves between \$4.00 and \$7.00 in
20 reduced drug-related crime, criminal justice costs, and theft. Earlier

1 intervention to provide services before major problems develop can save even
2 more.

3 Second: In Sec. 3, risk and needs screening tools and services, in
4 subsection (g), by inserting at the end of the subsection The recommendation
5 for the system for referral shall be inclusive of all initiatives within the Agency
6 of Human Services, including those within the Blueprint for Health and
7 Screening, Brief Intervention, and Referral for Treatment (SBIRT), as well as
8 initiatives within the Green Mountain Care Board and the State Innovation
9 Model (SIM) grant.

10 Third: In Sec. 11, DVHA Authority, following the word “prescribers” by
11 inserting , whether practicing in or outside the State of Vermont,

12 Fourth: By striking out Sec. 12 in its entirety and inserting in lieu thereof a
13 new Sec. 12 to read:

14 Sec. 12. CONTINUED MEDICATION-ASSISTED TREATMENT FOR
15 INCARCERATED PERSONS

16 (a) The Department of Corrections, in consultation with the Medication-
17 Assisted Treatment for Inmates Work Group created by 2013 Acts and
18 Resolves No. 67, Sec. 11, shall develop and implement a one-year
19 demonstration project to pilot the continued use of medication-assisted
20 treatment within Department facilities for detainees and sentenced inmates.

1 (b) The Commissioner of Corrections shall publish an interim revision
2 memorandum to replace Directive 363.01. The Medication-Assisted
3 Treatment for Inmates Work Group shall provide details of the demonstration
4 project, including:

5 (1) an update on the implementation of the recommendations provided
6 in the “Medication-Assisted Treatment for Inmates: Work Group Report and
7 Recommendations” submitted to the Vermont General Assembly on November
8 26, 2013;

9 (2) medication-assisted treatment time frames;

10 (3) Department protocols for detainees and inmates transitioning in and
11 out of treatment settings, or between correctional facilities and treatment
12 services;

13 (4) protocols regarding medical tapers, detoxification, and withdrawal;

14 (5) plans and timing for expansion of the pilot program; and

15 (6) an evaluation plan that includes appropriate metrics for determining
16 treatment efficacy, reincarceration episodes, Department- and
17 community-based collaboration challenges, and system costs.

18 (c) The Department shall enter into memoranda of understanding with the
19 Department of Health and with hub treatment providers regarding ongoing
20 medication-assisted treatment for persons in the custody of the Department.

1 (d) The Department shall collaborate with the Department of Health to
2 facilitate the provision of opioid overdose prevention training for persons who
3 are incarcerated and distribution of overdose rescue kits with naloxone at
4 correctional facilities to persons who are transitioning from incarceration back
5 into the community.

6 (e) The Departments of Corrections and of Health shall continue the
7 Medication-Assisted Treatment for Inmates Work Group created by 2013 Acts
8 and Resolves No. 67, Sec. 11, to inform and monitor implementation of the
9 demonstration project. The Departments shall evaluate the demonstration
10 project and provision of medication-assisted treatment to persons who are
11 incarcerated in Vermont and report their findings to the House Committees on
12 Corrections and Institutions, on Human Services, and on Judiciary and the
13 Senate Committees on Health and Welfare and on Judiciary on or before
14 January 1, 2015.

15 Fifth: By striking out Sec. 13 in its entirety and inserting in lieu thereof a
16 new Sec. 13 to read:

17 Sec. 13. VPMS QUERY; RULEMAKING

18 The Secretary of Human Services shall adopt rules requiring:

19 (1) All Medicaid participating providers, whether licensed in or outside
20 Vermont, who prescribe buprenorphine or a drug containing buprenorphine to
21 a Vermont Medicaid beneficiary to query the Vermont Prescription Monitoring

1 System the first time they prescribe buprenorphine or a drug containing
2 buprenorphine for the patient and at regular intervals thereafter. Regular
3 intervals may exceed the requirements for other Schedule III pharmaceuticals,
4 and shall be done at least annually, in case of clinical concern, and prior to
5 prescribing a replacement prescription. The rules shall also include dosage
6 thresholds, which may be exceeded only with prior approval from the Chief
7 Medical Officer of the Department of Vermont Health Access or designee.

8 (2) All providers licensed in Vermont who prescribe buprenorphine or a
9 drug containing buprenorphine to a Vermont patient who is not a Medicaid
10 beneficiary to query the Vermont Prescription Monitoring System the first time
11 they prescribe buprenorphine or a drug containing buprenorphine for the
12 patient and at regular intervals thereafter. Regular intervals may exceed the
13 requirements for other Schedule III pharmaceuticals and shall be done at least
14 annually, in case of clinical concern, and prior to prescribing a replacement
15 prescription. The rules shall also include dosage thresholds.

16 Sixth: In Sec. 14, medication-assisted therapy, by striking out all following
17 “ensure that their patients” and inserting in lieu thereof: are screened or
18 assessed to determine their need for counseling and that patients who are
19 determined to need counseling or other support services receive are referred
20 from a licensed clinical professional for appropriate substance abuse
21 counseling or other services as needed.

1 Seventh: By striking out Sec. 15 in its entirety and inserting in lieu thereof
2 a new Sec. 15 to read:

3 Sec. 15. 26 V.S.A. chapter 36, subchapter 8 is added to read:

4 Subchapter 8. Naloxone Hydrochloride

5 § 2080. NALOXONE HYDROCHLORIDE; DISPENSING OR

6 FURNISHING

7 (a) The Board of Pharmacy shall adopt protocols for licensed pharmacists
8 to dispense or otherwise furnish naloxone hydrochloride to patients who do not
9 hold an individual prescription for naloxone hydrochloride. Such protocols
10 shall be consistent with rules adopted by the Commissioner of Health.

11 (b) Notwithstanding any provision of law to the contrary, a licensed
12 pharmacist may dispense naloxone hydrochloride to any person as long as the
13 pharmacist complies with the protocols adopted pursuant to subsection (a) of
14 this section.

15

16

17 (Committee vote: _____)

18

19

Representative _____

20

FOR THE COMMITTEE